Search Results

Momelotinib 2 mg  | 98.75%

TargetMol

Momelotinib is an orally bioavailable small-molecule inhibitor of Janus kinases 1 and 2 (JAK1/2) with IC50 of 11 nM/18 nM. JAK1/2 inhibitor CYT387 competes with JAK1/2 for ATP binding, which may result in inhibition of JAK1/2 activation, inhibition of the JAK-STAT signaling pathway, and so the induction of apoptosis and a reduction of tumor cell […]

More Information Supplier Page

Taselisib 100 mg  | 99.46%

TargetMol

Taselisib is an orally bioavailable inhibitor of the class I phosphatidylinositol 3-kinase (PI3K) alpha isoform (PIK3CA), with potential antineoplastic activity.

More Information Supplier Page

Taselisib 2 mg  | 99.46%

TargetMol

Taselisib is an orally bioavailable inhibitor of the class I phosphatidylinositol 3-kinase (PI3K) alpha isoform (PIK3CA), with potential antineoplastic activity.

More Information Supplier Page

(S)-P7C3-OMe 100 mg  | 99.61%

TargetMol

(S)-P7C3-OMe is a methoxy derivative of parent compound P7C3, an aminopropyl carbazole that exhibits antidepressant and neuroprotective activities.

More Information Supplier Page

Anacetrapib 2 mg  | 97.09%

TargetMol

Anacetrapib (MK0859) is an effective, specific, reversible rhCETP and mutant CETP(C13S) inhibitor (IC50: 7.9 nM and 11.8 nM). Anacetrapib reduces the transfer of cholesteryl ester from HDL to LDL and/or VLDL thereby, producing an increase in serum HDL-cholesterol levels and a decrease in serum LDL-cholesterol levels.

More Information Supplier Page

Momelotinib 200 mg  | 98.75%

TargetMol

Momelotinib is an orally bioavailable small-molecule inhibitor of Janus kinases 1 and 2 (JAK1/2) with IC50 of 11 nM/18 nM. JAK1/2 inhibitor CYT387 competes with JAK1/2 for ATP binding, which may result in inhibition of JAK1/2 activation, inhibition of the JAK-STAT signaling pathway, and so the induction of apoptosis and a reduction of tumor cell […]

More Information Supplier Page

Momelotinib 25 mg  | 98.75%

TargetMol

Momelotinib is an orally bioavailable small-molecule inhibitor of Janus kinases 1 and 2 (JAK1/2) with IC50 of 11 nM/18 nM. JAK1/2 inhibitor CYT387 competes with JAK1/2 for ATP binding, which may result in inhibition of JAK1/2 activation, inhibition of the JAK-STAT signaling pathway, and so the induction of apoptosis and a reduction of tumor cell […]

More Information Supplier Page

Candesartan 100 mg  | 98.28%

TargetMol

Candesartan is an angiotensin II receptor blocker used widely in the therapy of hypertension and heart failure.

More Information Supplier Page